Related references
Note: Only part of the references are listed.No detectable resistance to tenofovir disoproxil fumarate in HBeAg plus and HBeAg- patients with chronic hepatitis B after 8years of treatment
Y. Liu et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy
Elham Shirvani-Dastgerdi et al.
JOURNAL OF HEPATOLOGY (2017)
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung et al.
JOURNAL OF HEPATOLOGY (2017)
Tenofovir alafenamide demonstrates broad cross-genotype activity 'against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro
Yang Liu et al.
ANTIVIRAL RESEARCH (2017)
A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
David Wohl et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy
Eisuke Murakami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
Christian Callebaut et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E. Sax et al.
LANCET (2015)
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
Aparna Schweitzer et al.
LANCET (2015)
No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B
Amoreena C. Corsa et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B
Scott Fung et al.
GASTROENTEROLOGY (2014)
No Detectable Resistance to Tenofovir Disoproxil Fumarate After 6 Years of Therapy in Patients With Chronic Hepatitis B
Kathryn M. Kitrinos et al.
HEPATOLOGY (2014)
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2014)
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
Stuart C. Gordon et al.
HEPATOLOGY (2013)
Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340
Darius Babusis et al.
MOLECULAR PHARMACEUTICS (2013)
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
Fabien Zoulim et al.
LIVER INTERNATIONAL (2013)
HBVdb: a knowledge database for Hepatitis B Virus
Juliette Hayer et al.
NUCLEIC ACIDS RESEARCH (2013)
De novo assembly of highly diverse viral populations
Xiao Yang et al.
BMC GENOMICS (2012)
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
S. J. Patterson et al.
GUT (2011)
Virological Breakthrough and Resistance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues in Clinical Practice
Chanunta Hongthanakorn et al.
HEPATOLOGY (2011)
HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays
Yuao Zhu et al.
JOURNAL OF VIROLOGICAL METHODS (2011)
Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues
Florian van Boemmel et al.
HEPATOLOGY (2010)
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Fabien Zoulim et al.
GASTROENTEROLOGY (2009)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance
Bulent Degertekin et al.
JOURNAL OF HEPATOLOGY (2009)
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure
Stephanie Villet et al.
JOURNAL OF HEPATOLOGY (2008)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro
Nadia Warner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
Entecavir resistance is rare in nucleoside naive patients with hepatitis B
Richard J. Colonno et al.
HEPATOLOGY (2006)
Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif
Hiromi Yatsuji et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus
WE Delaney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro
WE Delaney et al.
JOURNAL OF VIROLOGY (2003)
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
P Angus et al.
GASTROENTEROLOGY (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
ASF Lok et al.
GASTROENTEROLOGY (2003)
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
SK Ono et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
CT Yeh et al.
HEPATOLOGY (2000)
Share Paper
